Humana Inc. (NYSE:HUM) Shares Acquired by Forsta AP Fonden

Forsta AP Fonden boosted its position in Humana Inc. (NYSE:HUM) by 2.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,200 shares of the insurance provider’s stock after acquiring an additional 500 shares during the quarter. Forsta AP Fonden’s holdings in Humana were worth $6,393,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV raised its stake in shares of Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 61 shares during the period. Atwood & Palmer Inc. acquired a new stake in Humana in the 3rd quarter valued at $29,000. Ashton Thomas Securities LLC purchased a new position in Humana in the third quarter valued at about $31,000. Your Advocates Ltd. LLP lifted its stake in shares of Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares in the last quarter. Finally, LRI Investments LLC boosted its position in shares of Humana by 1,021.4% in the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after buying an additional 143 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Humana Stock Down 1.2 %

NYSE:HUM opened at $293.40 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a 50 day moving average of $275.45 and a 200-day moving average of $303.03. The firm has a market capitalization of $35.33 billion, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.22 and a beta of 0.55. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Analysts predict that Humana Inc. will post 16.11 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on HUM. KeyCorp assumed coverage on Humana in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. Morgan Stanley upped their target price on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Piper Sandler raised their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Wells Fargo & Company cut their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, Royal Bank of Canada lowered their target price on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Nineteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus price target of $297.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.